Top Markets
Coin of the day
Artiva Biotherapeutics, Inc. Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTV
株式のランク #12869
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm... Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
株価
$11.09
最終同期: 2026-08-28
時価総額
$542.19M
変化(1日)
-7.12%
変化(1年)
252.06%
US
取引 Artiva Biotherapeutics, Inc. (ARTV)

カテゴリー

Artiva Biotherapeutics, Inc.(ARTV)の株価履歴
終値の最高値: $11.49 (2026-08-01)

終値の最安値: $11.87 (2024-07-01)
Artiva Biotherapeutics, Inc. の株価履歴(2024 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) 59.60%
2025 -64.18%
2024 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.01 -13.08%
AU
$138.18 473.58%
US
$752.76 6.28%
CH